Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients

PurposeThe presence of a bulky tumour at staging on CT is an independent prognostic factor in malignant lymphomas. However, its prognostic value is limited in diffuse disease. Total metabolic tumour volume (TMTV) determined on 18F-FDG PET/CT could give a better evaluation of the total tumour burden and may help patient stratification. Different methods of TMTV measurement established in phantoms simulating lymphoma tumours were investigated and validated in 40 patients with Hodgkin lymphoma and diffuse large B-cell lymphoma.MethodsData were processed by two nuclear medicine physicians in Reggio Emilia and Créteil. Nineteen phantoms filled with 18F-saline were scanned; these comprised spherical or irregular volumes from 0.5 to 650 cm3 with tumour-to-background ratios from 1.65 to 40. Volumes were measured with different SUVmax thresholds. In patients, TMTV was measured on PET at staging by two methods: volumes of individual lesions were measured using a fixed 41 % SUVmax threshold (TMTV41) and a variable visually adjusted SUVmax threshold (TMTVvar).ResultsIn phantoms, the 41 % threshold gave the best concordance between measured and actual volumes. Interobserver agreement was almost perfect. In patients, the agreement between the reviewers for TMTV41 measurement was substantial (ρc = 0.986, CI 0.97 – 0.99) and the difference between the means was not significant (212 ± 218 cm3 for Créteil vs. 206 ± 219 cm3 for Reggio Emilia, P = 0.65). By contrast the agreement was poor for TMTVvar. There was a significant direct correlation between TMTV41 and normalized LDH (r = 0.652, CI 0.42 – 0.8, P <0.001). Higher disease stages and bulky tumour were associated with higher TMTV41, but high TMTV41 could be found in patients with stage 1/2 or nonbulky tumour.ConclusionMeasurement of baseline TMTV in lymphoma using a fixed 41% SUVmax threshold is reproducible and correlates with the other parameters for tumour mass evaluation. It should be evaluated in prospective studies.

[1]  M. Dreyling,et al.  Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Ronald Boellaard,et al.  Repeatability of Metabolically Active Volume Measurements with 18F-FDG and 18F-FLT PET in Non–Small Cell Lung Cancer , 2010, The Journal of Nuclear Medicine.

[3]  H. Tilly,et al.  Prognostic value of pretherapy metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in patients with diffuse large B-cell lymphoma (DLBCL) , 2012 .

[4]  S M Larson,et al.  Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding , 1997, Cancer.

[5]  W. Oyen,et al.  FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  B. Coiffier,et al.  Baseline Metabolic Tumor Volume Is Predictive of Patient Outcome in Diffuse Large B Cell Lymphoma , 2012 .

[7]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[8]  P. Moreau,et al.  Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma , 2008, Haematologica.

[9]  U. Jaeger,et al.  Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. , 2008, The Lancet. Oncology.

[10]  M. Dimopoulos,et al.  Re‐evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents , 2013, Hematological oncology.

[11]  Ho-Jin Shin,et al.  Prognostic value of metabolic tumor volume on PET / CT in primary gastrointestinal diffuse large B cell lymphoma , 2012, Cancer science.

[12]  G. Mahon A Proposal for Strength-of-Agreement Criteria for Lin’s Concordance Correlation Coefficient , 2005 .

[13]  L. Lin,et al.  A concordance correlation coefficient to evaluate reproducibility. , 1989, Biometrics.

[14]  Peter Smeets,et al.  Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  J. Armitage,et al.  A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.

[16]  Nico Karssemeijer,et al.  A novel iterative method for lesion delineation and volumetric quantification with FDG PET , 2007, Nuclear medicine communications.

[17]  Robert B. McBride,et al.  A proposal for strength-of-agreement criteria for Lins Concordance Correlation Coefficient , 2005 .

[18]  Seong-Jang Kim,et al.  Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma , 2013, Cancer science.

[19]  P. Gobbi,et al.  Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy , 2012, Hematological oncology.

[20]  P. Moreau,et al.  Efficacy of FDG-PET/CT Imaging To Guide Biopsies in the Detection of Richter’s Syndrome. , 2007 .

[21]  B. Coiffier,et al.  SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. , 2011, Blood.

[22]  Seong-Jang Kim,et al.  Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement , 2011, Annals of Hematology.

[23]  Aswin L Hoffmann,et al.  Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer. , 2007, International journal of radiation oncology, biology, physics.

[24]  Paul Kinahan,et al.  Tumor delineation using PET in head and neck cancers: threshold contouring and lesion volumes. , 2006, Medical physics.

[25]  Klemens Scheidhauer,et al.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  I. Buvat,et al.  Comparative Assessment of Methods for Estimating Tumor Volume and Standardized Uptake Value in 18F-FDG PET , 2010, Journal of Nuclear Medicine.

[27]  Y. Erdi,et al.  Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  H. Barnhart,et al.  An Overview on Assessing Agreement with Continuous Measurements , 2007, Journal of biopharmaceutical statistics.

[29]  A. Alavi,et al.  Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET , 2008, Nuclear medicine communications.

[30]  Andreas Bockisch,et al.  Segmentation of PET volumes by iterative image thresholding. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  M. Federico,et al.  Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy , 2011, Leukemia & lymphoma.

[32]  C. Rübe,et al.  Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  A. López-Guillermo,et al.  CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. , 2011, The Lancet. Oncology.

[34]  S. Barrington,et al.  does Quantitative Pet-ct Predict Prognosis In Diffuse Large Bcell Lymphoma (dlbcl)? : 014 , 2013 .

[35]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[36]  M. Dreyling,et al.  Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.